Add BrightSurf on Google Email

Terasaki Institute researchers reveal vagus nerve modulation as key to combating cancer-associated cachexia featured in cell

The study demonstrates that modulating the vagus nerve can effectively halt the progression of cachexia, enhance chemotherapy outcomes, and improve survival in preclinical models. This intervention restores normal liver metabolism, reduces systemic inflammation, and alleviates cachectic symptoms.

SourceTerasaki Institute for Biomedical Innovation·JournalCell·TypeExperimental study·DateAug 14, 2025

Construction of region-specific liver organoid and fabrication of hierarchical functional liver lobule for liver disease modeling and drug evaluation

Researchers developed a human liver organoid platform that closely replicates the liver's region-specific functional architecture, enabling disease modeling and drug screening. The system demonstrated high sensitivity in pharmacological assays and supported region-specific hepatocyte differentiation.

SourceScience China Press·JournalScience Bulletin·TypeExperimental study·DateAug 5, 2025

Chungnam National University researchers reveal how vitamin D is shown to reduce liver damage by boosting TXNIP activity in cholangiocytes

Researchers found that vitamin D supplementation reduces liver inflammation and fibrosis in patients with chronic liver disease by upregulating the TXNIP gene in ductular cells. The study provides new insights into the underlying mechanisms of liver diseases and offers a potential therapeutic target for improving outcomes.

SourceChungnam National University Evaluation Team·JournalNature Communications·TypeExperimental study·DateJul 28, 2025

New review highlights protective strategies against hepatic ischemia-reperfusion injury

A comprehensive review in Current Molecular Pharmacology explores the mechanisms of hepatic ischemia-reperfusion injury (IRI) and emerging treatments. Effective strategies include antioxidant administration, surgical preconditioning, and herbal compounds with anti-inflammatory and antioxidant properties.

SourceFAR Publishing Limited·JournalCurrent Molecular Pharmacology·TypeLiterature review·DateJul 27, 2025

Cannabidiol and liver enzyme level elevations in healthy adults

A randomized clinical trial found that cannabidiol (CBD) administration led to liver enzyme level elevations in 5.6% of participants and potential drug-induced liver injury in 4.9%. Hepatic enzymes returned to normal within weeks after discontinuation. Further research is needed on CBD's long-term effects and safety.

SourceJAMA Network·JournalJAMA Internal Medicine·DateJul 7, 2025

AI detects fatty liver disease with chest X-rays

A research team at Osaka Metropolitan University has developed an AI model that can detect fatty liver disease from chest X-ray images with an accuracy rate of 0.82-0.83. This breakthrough has the potential to improve early detection and treatment of the disease, which affects one in four people worldwide.

SourceOsaka Metropolitan University·JournalRadiology Cardiothoracic Imaging·TypeImaging analysis·DateJun 27, 2025

Liver organoid breakthrough: Generating organ-specific blood vessels

Researchers at Cincinnati Children's Hospital Medical Center have successfully grown liver tissue that can produce its own internal blood vessels. This breakthrough could lead to new treatments for people living with hemophilia and those experiencing acute or chronic liver failure, as the liver organoids can secrete coagulation factors.

SourceCincinnati Children's Hospital Medical Center·JournalNature Biomedical Engineering·TypeExperimental study·DateJun 25, 2025

Alcohol-associated liver disease mortality

This cross-sectional study reveals a substantial rise in alcohol-associated liver disease mortality, particularly among women and younger adults. The findings highlight the importance of targeted public health initiatives to address this growing health concern.

SourceJAMA Network·JournalJAMA Network Open·DateJun 11, 2025

Diabetes drug shows benefits for patients with liver disease

A clinical trial found that dapagliflozin improved metabolic dysfunction-associated steatohepatitis and liver fibrosis in patients with progressive liver disease, a condition affecting over 5% of adults. The treatment also showed resolution of inflammation and improvement without worsening of fibrosis.

SourceBMJ Group·JournalThe BMJ·TypeRandomized controlled/clinical trial·DateJun 4, 2025

Liver cancer survival rates reflect income disparities

A study published in The Lancet Regional Health – Europe found that patients with low household income were more likely to be diagnosed late and receive less effective treatment for liver cancer. This highlights the need for targeted screening in deprived areas to improve early diagnosis and survival rates.

SourceUniversity of Gothenburg·JournalThe Lancet Regional Health - Europe·TypeObservational study·DateMay 5, 2025

Improved discrimination and predictive ability of novel prognostic scores for long-term mortality in hospitalized patients with cirrhosis

Researchers found novel prognostic scores, such as MELD 3.0/GEMA-Na, exhibit superior discrimination and predictive ability for all-cause mortality up to two years in hospitalized patients with cirrhosis. The study suggests these scores are essential for risk stratification and may improve patient outcomes.

SourceXia & He Publishing Inc.·JournalJournal of Clinical and Translational Hepatology·DateApr 29, 2025

The potential oncogenic role of serum-derived hsa_circ_101555 as a non-invasive diagnostic/prognostic marker in patients with hepatocellular carcinoma

The study found that serum-derived hsa_circ_101555 showed excellent diagnostic accuracy in differentiating HCC patients from healthy controls. It also demonstrated a prognostic role in predicting tumor progression and response to therapy, with significant correlations with markers of liver inflammation and tumor features.

SourceXia & He Publishing Inc.·JournalGene Expression·DateApr 24, 2025

Obesity disrupts “reaction time” to starvation in mice

Researchers found that obesity causes a disruption in the liver's ability to adapt to starvation, specifically in the temporal coordination of molecules. This suggests that obesity makes the body more vulnerable to the negative effects of starvation, despite no significant structural disruptions in the molecular network.

SourceSchool of Science, The University of Tokyo·JournalScience Signaling·TypeData/statistical analysis·DateApr 22, 2025

Ursolic acid modulates estrogen conversion to relieve inflammation in metabolic dysfunction-associated steatotic liver disease via HSD17B14

Researchers investigated the therapeutic mechanisms of ursolic acid on metabolic dysfunction-associated steatotic liver disease. Ursolic acid was found to reduce inflammation by modulating estrogen conversion via HSD17B14, a crucial enzyme regulating estrogen balance.

SourceXia & He Publishing Inc.·JournalJournal of Clinical and Translational Hepatology·DateApr 21, 2025

Inhibition of cyclooxygenase-2 upregulates the nuclear factor erythroid 2-related factor 2 signaling pathway to mitigate hepatocyte ferroptosis in chronic liver injury

This study found that inhibiting cyclooxygenase-2 reduces liver ferroptosis and fibrosis by upregulating the Nrf2 signaling pathway. COX-2 inhibition also restored antioxidant defenses in hepatocytes, reducing oxidative stress and lipid peroxidation.

SourceXia & He Publishing Inc.·JournalJournal of Clinical and Translational Hepatology·DateApr 18, 2025

Mitochondrial membrane potential of CD8+ T cells predicts bacterial infection and rapid development of acute-on-chronic liver failure in cirrhotic patients

The study found that mitochondrial membrane potential (MMP) of CD8+ T cells is a significant predictor of bacterial infection (BI) and acute-on-chronic liver failure (ACLF) in cirrhotic patients. Low MMP levels were associated with increased risk of BI and ACLF.

SourceXia & He Publishing Inc.·JournalJournal of Clinical and Translational Hepatology·DateApr 17, 2025

New human “multi-zonal” liver organoids improve injury survival in rodents

A team of experts at Cincinnati Children's reports achieving a milestone in growing human liver organoid tissue that faithfully reproduces key zones, nearly doubling rodent survival rate. This breakthrough paves the way for studying human liver biology and disease, accelerating drug development and potentially leading to repair tissues.

SourceCincinnati Children's Hospital Medical Center·JournalNature·TypeExperimental study·DateApr 16, 2025

Hepatocellular carcinoma and the role of liver transplantation

Hepatocellular carcinoma is the most prevalent form of liver cancer, and liver transplantation offers a curative treatment option for appropriately selected patients. Bridging therapies, such as radiofrequency ablation and transarterial chemoembolization, can improve survival outcomes post-transplant by preventing tumor progression.

SourceXia & He Publishing Inc.·JournalJournal of Clinical and Translational Hepatology·DateApr 15, 2025

Uncovering the molecular drivers of liver cancer

A study published in Journal of Proteome Research reveals that inflammation and aging contribute to the development of non-viral liver cancer. Researchers analyzed gene expression and metabolites in normal and affected samples, identifying potential therapeutic targets for chemoprevention.

SourceHiroshima University·JournalJournal of Proteome Research·DateApr 15, 2025

Innovative phospholipids enhance mRNA delivery

A new class of zwitterionic phospholipids, DOPE-Cx, enhances the functional delivery of mRNA via lipid nanoparticles, overcoming endosomal escape and improving mRNA expression. This breakthrough paves the way for advanced therapeutic applications, including mRNA vaccines, cancer treatment, and protein replacement therapy.

SourceHokkaido University·JournalAdvanced Science·TypeExperimental study·DateMar 28, 2025

Beyond the cure: Navigating hepatocellular risk and surveillance after hepatitis C eradication in the direct-acting antiviral era

Direct-acting antivirals have reduced HCV-related morbidity and mortality, but hepatocellular carcinoma (HCC) risk persists in certain populations. Risk factors include pre-treatment cirrhosis, metabolic disorders, and advanced fibrosis, highlighting the need for tailored surveillance strategies.

SourceXia & He Publishing Inc.·JournalJournal of Clinical and Translational Hepatology·DateMar 20, 2025